z-logo
Premium
Disruption of the PI3K axis abrogates ionizing radiation‐induced cell death
Author(s) -
Lazo John S.,
Epperly Michael W.,
Sharlow Elizabeth R.,
Lira Ana,
Skoda Erin M.,
Wipf Peter,
Kagan Valerian E.,
Greenberger Joel S.
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1181.7
Subject(s) - ionizing radiation , pi3k/akt/mtor pathway , programmed cell death , cancer research , ly294002 , small interfering rna , apoptosis , biology , microbiology and biotechnology , chemistry , transfection , cell culture , irradiation , genetics , physics , nuclear physics
Effective and safe therapies are lacking to abrogate the lethal effects of accidental or intentional public exposure to toxic doses of ionizing radiation. Our recent unbiased phenotypic screen using a sentinel human pluripotent cell line and a small interfering RNA (siRNA) library targeting druggable genes implicated the phosphoinositide‐3‐kinase (PI3K) pathway in cellular death after ionizing radiation. Using a model of embryonic stem cells, we now demonstrate that the prototype PI3K inhibitor LY294002 as well a new PI3K inhibitor class EMF388–021 mitigated the lethal effects of ionizing radiation including the induction of apoptosis. Moreover, a single intraperitoneal dose of LY294002 (30 mg/kg) given 4 or 24 h after 9.25 Gy of total body irradiation significantly reduced death. Similarly, a single intraperitoneal dose of EMF388–021 (10 mg/kg) given 4 h after 9.25 Gy of ionizing radiation markedly reduced lethality. We found PI3K inhibition stimulated radiation‐induced autophagic flux and reduced mitochondrial respiration providing potential mechanisms for the radiation mitigation. This study documents that an unbiased siRNA assay can assist in the identification of pharmacologically useful radiation mitigators and implicates the PI3K pathway in the human radiation response.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here